BioPharma Dive January 16, 2025
AbbVie’s CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained what it got wrong forecasting GLP-1 drug demand.
SAN FRANCISCO — With the close of J.P. Morgan Healthcare Conference, attention turns to next week’s inauguration of President-elect Donald Trump, and what his administration might mean for the Food and Drug Administration and the Department of Health and Human Services.
By and large, pharma executives and investors here are largely saying they remain confident in the stability of regulatory processes, despite headlines around the potential for disruption. Some aren’t expecting much to change if Marty Makary, a Johns Hopkins surgeon and Trump’s pick to run the FDA, is confirmed by the...
Today's Sponsors
Today's Sponsor